Atomoxetine Hcl
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Atomoxetine Hydrochloride: Repurposing Evaluation — Insufficient Evidence Pack Data
One-Sentence Summary
Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor (NRI) licensed in multiple countries for the treatment of attention-deficit/hyperactivity disorder (ADHD). The current Evidence Pack contains no TxGNN-predicted new indications and several unresolved data gaps of blocking or high severity. A full repurposing evaluation cannot be completed until these gaps are remediated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) (from general pharmacological knowledge; not recorded in Evidence Pack) |
| Predicted New Indication | None available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — prediction stage not reached |
| UK Market Status | Not recorded in Evidence Pack (see note below) |
| Number of Marketing Authorisations | 0 (per Evidence Pack) |
| Recommended Decision | Hold |
⚠ Market Status Discrepancy: The Evidence Pack records zero MHRA licences and a “not marketed” status. This is inconsistent with known regulatory information: atomoxetine (Strattera®, Eli Lilly) holds MHRA marketing authorisation for ADHD in children, adolescents, and adults, and is listed in the BNF (Chapter 4 — CNS stimulants and other drugs for ADHD). The MHRA regulatory data collection step should be re-run before this report is finalised.
Why is This Prediction Reasonable?
No TxGNN prediction has been generated for this candidate, so no formal mechanism-to-new-indication bridge can be constructed at this stage.
From general pharmacological knowledge: atomoxetine is a potent and selective inhibitor of the presynaptic norepinephrine transporter (NET), increasing norepinephrine availability primarily in the prefrontal cortex. Unlike methylphenidate and amphetamine-based treatments, it has no clinically significant dopamine transporter (DAT) activity at therapeutic doses, which underpins its status as a non-controlled medicine in the UK — a practically important distinction for prescribers.
Until the TxGNN prediction pipeline has been re-run with a confirmed DrugBank ID and mechanism of action, a mechanistically reasoned repurposing hypothesis cannot be presented. Please refer to the data gap remediation steps in the Conclusion section below.
Clinical Trial Evidence
Currently no clinical trial evidence is linked to a predicted repurposing indication. Once a TxGNN prediction is available, this section will be populated with relevant registered trials from ClinicalTrials.gov, ISRCTN, and the EU Clinical Trials Register.
Literature Evidence
Currently no literature evidence is linked to a predicted repurposing indication. Once a TxGNN prediction is available, this section will be populated with relevant PubMed publications.
UK Market Information
The Evidence Pack records no MHRA marketing authorisations for this drug. As noted above, this appears to be a data collection gap rather than a true absence of authorisation. The table below cannot be populated until the MHRA data collection step is successfully re-run.
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not recorded — data collection required | — | — | — |
Safety Considerations
No safety data is available in the current Evidence Pack. Please refer to the Strattera Summary of Product Characteristics (SmPC) available via the MHRA or electronic Medicines Compendium (emc), and consult BNF Chapter 4 for prescribing guidance. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk).
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack contains no TxGNN-predicted indications, no MHRA licence data, and no safety information; a meaningful repurposing evaluation is not possible without first resolving the outstanding data gaps.
To proceed, the following is needed:
- Resolve Blocking Data Gap (DG001) — MHRA SmPC warnings and contraindications: Download the Strattera SmPC PDF from the MHRA website or emc (https://www.medicines.org.uk/emc) and parse key warnings and contraindications.
- Resolve High-Priority Data Gap (DG002) — Mechanism of action: The DrugBank ID is currently null. Search the DrugBank API using the INN “atomoxetine” to retrieve the confirmed DrugBank ID, full MOA, pharmacodynamic data, and toxicity profiles.
- Re-run MHRA regulatory data collection: Repopulate licence records to correctly reflect Strattera’s current MHRA authorisation status, dosage forms, and approved indications.
- Re-run TxGNN prediction pipeline: Once the DrugBank ID, MOA, and regulatory data are confirmed, resubmit the drug to the TxGNN model to generate ranked repurposing candidates with confidence scores.
- Collect drug interaction data: No DDI records were returned. Once the DrugBank ID is confirmed, re-query the DrugBank interaction database and cross-reference with the MHRA/BNF interaction checker.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.